Liraglutide trial: results

Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living…

Nicotinamide riboside for Parkinson’s: pilot results published

Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson’s.

Diabetes dual agonist drugs for Parkinson’s

Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of treatment for diabetes which target GLP-1R and another protein called gastric inhibitory polypeptide (or GIP) at the same time. These combination…

GCase and Parkinson’s: a new perspective

Recently researchers have provided new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.

News Research news

Clinical results from Enterin trial

Biotech company Enterin has announced the results of their phase 2 clinical trial of ENT-01 indicating that it had a positive benefit on the gut symptoms associated with Parkinson’s.